NEW YORK (GenomeWeb News) – Genome customization firm Cellectis bioresearch today announced it has won a five-year, $9.5 million contract from the National Institutes of Health for work directed at induced pluripotent stem cells.

Under the terms of the contract, Cellectis bioresearch will provide services to NIH and certain other government agencies. The company will generate iPS cell lines of clinical grade and differentiate iPS cells toward specific tissue cell type of clinical grade.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."